CCL2 and myocardial infarction: Studies in mouse models of Alzheimer’s disease, brain injury, myocardial infarction and inflammatory bowel disease could demonstrate a reduction in expression levels of interleukin-1 beta, interleukin-6, MCP-1 and NLRP3 upon treatment with pterostilbene and prebiotics38–41.